Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.
Joseph S Baxter1, Claudia Montiel Equihua1, Jan J Molenaar2
1LifeArc, London, UK.
British Journal of Cancer
|June 13, 2026
Summary
Developing targeted therapies for high-risk pediatric rhabdomyosarcoma is crucial. New strategies include targeting fusion proteins, using degraders, and exploring antibody-drug conjugates for better outcomes.
Area of Science:
- Pediatric Oncology
- Cancer Therapeutics
- Molecular Biology
Background:
- Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma.
- Survival rates vary significantly based on disease risk, with metastatic disease having poor outcomes (20-30%).
- There is an urgent need for novel therapeutics targeting high-risk rhabdomyosarcoma and reducing treatment toxicity.
Purpose of the Study:
- To identify and prioritize key therapeutic targets and strategies for rhabdomyosarcoma.
- To guide future preclinical and clinical development of novel treatments.
- To address the unmet need for effective therapies in high-risk and metastatic rhabdomyosarcoma.
Main Methods:
- Review and discussion of emerging therapeutic targets and approaches.
- Identification of priority targets including FGFR4, PAX3/7::FOXO1 fusion proteins, MYOD1, P300/CBP, TEAD, and B7-H3/CD276.
- Consideration of drug combinations, including MEK, BRAF, PI3K inhibitors, and Notch inhibitors.
Main Results:
- Several high-priority targets for therapeutic development were identified, including FGFR4, PAX3/7::FOXO1, MYOD1, TEAD, and B7-H3/CD276.
- Specific strategies like degraders (FGFR4, MYOD1, TEAD, P300/CBP) and antibody-drug conjugates (B7-H3/CD276) show promise.
- Combinatorial approaches involving MEK inhibitors with other agents are recommended for evaluation.
Conclusions:
- Targeted therapies and drug degraders represent promising avenues for rhabdomyosarcoma treatment.
- Further preclinical evaluation and optimized clinical trial design are essential for advancing these therapies.
- Addressing high-risk and metastatic disease requires innovative therapeutic strategies and combination approaches.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...